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a  b  s  t  r  a  c  t
Huntington’s  disease  (HD)  is a fatal  neurodegenerative  disease  caused  by  an  extended  polyglutamine  tract
in the  huntingtin  protein.  Circadian,  sleep  and  hypothalamic-pituitary-adrenal  (HPA)  axis  disturbances
are  observed  in  HD  as early  as  15 years  before  clinical  disease  onset.  Disturbances  in  these  key  processes
result  in  increased  cortisol  and  altered  melatonin  release  which  may  negatively  impact  on  brain-derived
neurotrophic  factor  (BDNF)  expression  and  contribute  to documented  neuropathological  and  clinical
disease  features.  This  review  describes  the  normal  interactions  between  neurotrophic  factors,  the  HPA-
axis and  circadian  rhythm,  as indicated  by  levels  of  BDNF,  cortisol  and  melatonin,  and  the  alterationsircadian rhythm
uprachiasmatic nucleus (SCN)
ypothalamus
ypothalamic-pituitary-adrenal (HPA) axis
rain-derived neurotrophic factor (BDNF)
in  these  intricately  balanced  networks  in HD.  We  also  discuss  the  implications  of  these  alterations  on
the  neurobiology  of  HD  and the  potential  to result  in  hypothalamic,  circadian,  and  sleep  pathologies.
Measurable  alterations  in these  pathways  provide  targets  that, if  treated  early,  may  reduce  degeneration
of  brain  structures.  We  therefore  focus  here  on  the  means  by which  multidisciplinary  therapy  could  be
utilised  as  a non-pharmaceutical  approach  to restore  the  balance  of  these  pathways.©  2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Huntington’s disease (HD) is a fatal autosomal dominant
eurodegenerative disease caused by an expanded cytosine-
denine-guanine (CAG) repeat sequence in exon 1 of the Huntingtin
ene (HTT) (The Huntington’s Disease Collaborative Research
roup, 1993). This expanded sequence encodes a mutant ver-
ion of the protein, huntingtin (mHTT), which is associated with
biquitous molecular and cellular anomalies, widespread neuronal
ysfunction and cell loss (Kim et al., 2014) and the presentation of
otor and non-motor features, including progressive impairments
n motor control, cognitive function and mood (Tabrizi et al., 2013).
vidence also indicates that individuals suffer from sleep distur-
ances (Morton, 2013; Hansotia et al., 1985; Wiegand et al., 1991;
iano et al., 2015; Arnulf et al., 2008; Lazar et al., 2015a), auto-
omic abnormalities (e.g. hyperhidrosis, micturition disturbances,
wallowing difﬁculties, sexual dysfunction, altered heart rate vari-
bility) (Andrich et al., 2002; Kobal et al., 2010) and metabolic
rregularities (Browne et al., 1997; Mazziotta et al., 1987), with
ome non-motor features, such as cognitive and sleep abnormali-
ies, emerging years before the onset of motor signs (Tabrizi et al.,
011; Lazar et al., 2015a).
Although the pathophysiology underlying the development and
rogression of these clinical features is complex, the accompanying
lterations in neuroendocrine signalling, including cortisol (Aziz
t al., 2009a; Hubers et al., 2015) and melatonin (Kalliolia et al.,
014; Aziz et al., 2009b) release, and changes in circadian rhythmic-
ty (Morton et al., 2005; Aziz et al., 2010) suggest that the activity of
he hypothalamic-pituitary-adrenal (HPA) axis and the suprachias-
atic nucleus (SCN) are impaired in HD (see Table 1 for summary of
D pathologies relevant to this review). Neuropathological changes
ncluding volume loss, the loss of orexin-releasing neurons and
ecreased protein levels of vasoactive intestinal peptide (VIP) and
rginine vasopressin (AVP) in the hypothalamus support this sup-
osition (Politis et al., 2008; Soneson et al., 2010; Petersén et al.,
005).
The HPA-axis is central to neuroendocrine signalling. Indeed,
n intricate balance exists between neuroendocrine signalling and
xpression of neurotrophic factors, particularly brain-derived neu-
otrophic factor (BDNF) (Issa et al., 2010; Smith et al., 1995a). In
his review, we present for the ﬁrst time the biological impact of
PA-axis dysfunction on circadian rhythm, neuroendocrine sig-
alling, and neurotrophic factor support in HD (for a diagrammatic
iew, see Fig. 1). We  also draw on existing evidence in ani-
al  models and patients with HD and other disorders to review
on-pharmaceutical treatment strategies, particularly multidisci-
linary therapy, exercise, cognitive therapy and social interaction,
hich may  positively impact on HPA-axis dysfunction and poten-
ial downstream mechanisms and thereby delay disease onset in
ndividuals with premanifest HD. Since candidate pharmaceuti-
al treatment strategies for HD have been reviewed recently (Ross
t al., 2014), here we detail non-pharmaceutical multidisciplinary
pproaches as they have been reported to exert beneﬁcial effects
n HPA-axis function, circadian rhythm and BDNF, are of minimal
ost and can be implemented throughout life with few side effects.
.1. Normal function of the HPA-axis and the SCN
The structures of the HPA-axis, including the hypothalamus,
ituitary and adrenal glands, function in a tightly regulated manner
o control responses to physiological and psychological stress, auto-
omic and immune functions and sleep-wake behaviour through
he release of hormones, such as cortisol, in a circadian manner
Webster Marketon and Glaser, 2008; Ulrich-Lai and Herman, 2009;
teiger, 2002).havioral Reviews 71 (2016) 444–454 445
The paraventricular nucleus (PVN) releases corticotrophin
releasing factor (CRF) into the hypophyseal portal system, where
it stimulates the release of adrenocorticotrophic hormone (ACTH)
from the corticotropes of the anterior pituitary (Rivier and Vale,
1983). ACTH is released into the systemic circulation and stimulates
the adrenal cortex to release glucocorticoids, such as corticosterone
in mice and cortisol in humans, which regulate responses to stress
in central and peripheral systems. These glucocorticoids then pro-
vide negative feedback, inhibiting further release of CRF and ACTH
by binding to glucocorticoid receptors (GRs) at the PVN and pitu-
itary level, inhibiting further HPA-axis activation via glucocorticoid
response elements (GREs) (Keller-Wood and Dallman, 1984).
Glucocorticoid release is subject to inputs from other brain
regions, particularly the amygdala, stria terminalis and hippocam-
pus, which are all regions fundamentally involved in emotional
regulation and memory (Hauger and Dautzenberg, 2000). However
the basal circadian release of glucocorticoids is facilitated by the
connection between the PVN and SCN.
The SCN is located in the anterior hypothalamus and functions
as the central circadian clock that is the principle site of circa-
dian rhythm coordination in mammals (Nishino et al., 1976). The
SCN receives information from the retina and other brain regions
and synchronises the circadian rhythms of the organism emerging
at cellular, physiological and behavioural levels to various zeitge-
bers, the most important of which is ambient light. Synchronization
is mediated through neural and humoral signals. On a molecular
level the circadian rhythm in mammals is based on an autoregu-
latory transcriptional-translational feedback mechanism involving
CLOCK and BMAL1 transcription factors and PERIOD (PER1, 2 and 3)
and CRYPTOCHROME (CRY 1 and 2) core clock genes (Gekakis et al.,
1998). This molecular clock regulates a considerable proportion of
the human genome. Importantly, through its connections with the
PVN and mediation of the HPA-axis, the SCN controls daily varia-
tions in melatonin and cortisol release which are involved, amongst
other things, in sleep-wake behaviour and autonomic arousal reg-
ulation.
More speciﬁcally, activity of the SCN is synchronised to
the environmental light-dark cycle directly through the retinal-
hypothalamic tract and indirectly through the retinogeniculate
pathways and conveys this information to other hypothalamic
nuclei, the reticular formation and the pineal gland, coordinat-
ing the diurnal activities of these brain regions (Brzezinski, 1997).
Melatonin coordinates circadian rhythms in response to the day-
night cycle and initiates the thermoregulatory cascade, decreasing
core body temperature to induce sleepiness (Brzezinski, 1997;
Krauchi et al., 2000). The circadian variation of core body tem-
perature is also associated with the internal structure of sleep,
particularly with the circadian rhythm of REM (Dijk and Czeisler,
1995).
1.2. Stress and the role of cortisol
Cortisol secretion follows a circadian rhythm in individuals with
normal sleep-wake cycles. Within the ﬁrst 30 min  of awakening,
cortisol levels increase by up to 75% (Pruessner et al., 1997). Cor-
tisol levels then tend to plateau and around midnight reach their
nadir. There is large variation in circadian cortisol levels between
individuals, however morning cortisol levels are relatively stable
intra-individually, allowing for measurement of the cortisol awak-
ening response (CAR), which serves as an indication of HPA-axis
function and circadian rhythmicity (Stone et al., 2001).
In addition to its natural circadian rhythm, cortisol is released
in response to physiological and psychological stress (Staufenbiel
et al., 2013). Stress has many contributing factors and occurs when
environmental demands surpass the individual’s coping abilities
(Fink, 2010). The response to stress, particularly adaptation, varies
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Table  1
Summary of HD pathologies relevant to this review article.
Pathologies in Huntington’s disease Evidence References
HPA-axis and SCN
pathologies
Mouse models:
• Hypothalamic degeneration, pituitary and adrenal pathologies
•  Loss of orexin-releasing neurons
Petersén et al. (2005), Du et al. (2012),
Sathasivam et al. (1999),Björkqvist
et al. (2006)
Premanifest HD
• Hypothalamic volume loss (shown by voxel-based morphometry)
Soneson et al. (2010)
Manifest HD:
•  Hypothalamic volume loss (shown by voxel-based morphometry)Loss of
neurons in the nucleus tuberalis lateralis (NTL) and lateral hypothalamus (at
post-mortem)
•  Loss of orexin-releasing neurons (at post-mortem)
• Decreased protein levels of vasoactive intestinal peptide (VIP) and arginine
vasopressin (AVP) (at post-mortem)
Petersén et al. (2005), Kremer et al.
(1990, 1991), Douaud et al. (2006),
Gabery et al. (2010), Kassubek et al.
(2004), Aziz et al. (2008),  van Wamelen
et al. (2013)
Increased cortisol levels Premanifest HD:
• Increases in the cortisol awakening response (CAR)
• Increased daily cortisol output
(Hubers et al., 2015; van Duijn et al.,
2010)
Decreased BDNF
Mouse models:
• Decreased brain BDNF levels
(Zuccato et al., 2005; Pang et al., 2006)
Manifest HD:
•  Reduction of between 53 and 82% of BDNF in the caudate and putamen (at
post-mortem)
(Ferrer et al., 2000)
Circadian rhythm
disturbances
Mouse models:
• Breakdown in rest-activity cycle
•  Dysregulation of circadian gene expression, particularly in the SCN
•  Reduced circadian rhythm of spontaneous electrical activity in SCN neurons
Morton et al. (2005), Kudo et al. (2011),
Maywood et al. (2010)
Manifest HD:
•  Disturbances in rest-activity proﬁles
• Abnormal day-night ratios
• Altered sleep-wake timing
Morton et al., (2005), Hurelbrink et al.
(2005)
Alterations in
melatonin release
Premanifest HD:
• Temporal spread of melatonin rise
Kalliolia et al. (2014)
Manifest HD:
•  Decreased mean and acrophase melatonin levels
•  Temporal spread of melatonin rise
•  Delayed rise phase
Kalliolia et al. (2014), Aziz et al. (2009b)
Sleep disturbances
Premanifest HD:
• Fragmented sleep proﬁle
• Decreased theta power during REM sleep
Lazar et al. (2015a)
Manifest HD:
•  Insomnia
•  Decreased REM
• Decreased slow wave sleep (SWS)
•  Decreased sleep efﬁciency
• Advanced sleep phase
• Frequent nocturnal awakenings
•  Increased periodic leg movements (PLMs)
Morton (2013), Hansotia et al. (1985),
Wiegand et al. (1991), Piano et al.
(2015), Arnulf et al. (2008), Morton
et al. (2005), Neutel et al. (2015)
Premanifest HD = individuals carrying the gene for Huntington’s disease who do not yet display overt motor signs, however may exhibit mild cognitive decline and
mood  disturbances; Manifest HD = individuals carrying the Huntington’s disease gene who display overt motor signs of disease, cognitive decline and mood distur-
bances; HD = Huntington’s disease; HPA-axis = hypothalamic-pituitary-adrenal axis; BDNF = brain-derived neurotrophic factor; SCN = suprachiasmatic nucleus; REM = rapid
eye  movement
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Fig. 1. The interrelated consequences of HPA-axis and circadian rhythm disruption on BDNF expression and sleep and the implications on neurobiology. Disruption of the
HPA-axis and circadian rhythmicity as a result of hypothalamic dysfunction facilitates alterations in cortisol release and disrupted sleep architecture. Conversely, disrupted
sleep  can lead to increased cortisol and negatively effect the circadian rhythm. Increased cortisol can also disrupt sleep architecture and the circadian rhythm. Circadian rhythm
abnormalities and increased cortisol can negatively effect the release of BDNF and this, in turn, can induce cognitive deﬁcits, disrupt sleep architecture and reduce neuronal
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DNF  = brain-derived neurotrophic factor.
mong individuals and is inﬂuenced by an individual’s resilience
Russo et al., 2012). The biological processes that occur in order
o allow the individual to adapt to environmental stressors are
ollectively termed allostasis and involve the release of cortisol
nd adrenalin among many other chemical mediators (Sterling and
yer, 1988; Juster et al., 2010).
Cortisol acts to maintain blood pressure, mobilise energy
esources and decrease inﬂammation (Fraser et al., 1999; Petrovsky
t al., 1998; Peckett et al., 2011). Although individuals have the
bility to adapt to these biological effects of cortisol, excessive
r insufﬁcient activation of the HPA-axis can contribute to mal-
daptive consequences, leading to pathology (McEwen and Stellar,
993).
.3. Pathological effects of chronic glucocorticoid release
Signiﬁcant increases in the CAR and daily cortisol output have
een documented in premanifest HD (preHD) compared to healthy
ontrols and manifest HD (Hubers et al., 2015; van Duijn et al.,
010; Shirbin et al., 2013), which implies disruption of the circa-
ian rhythm and therefore of the HPA-axis (Aziz et al., 2009a; Politis
t al., 2008).
Disruption of the HPA-axis leads to altered circadian release
f cortisol (Saper et al., 2005). Severe alterations in glucocorti-
oids have been shown to exacerbate excitotoxic processes in
eurons, predominantly those of the hippocampus (Sapolsky et al.,
988; Crochemore et al., 2005; Sorrells et al., 2014; Stein-Behrens
t al., 1994). Chronic exposure to glucocorticoids decreases neu-
ogenesis, arborisation of dendrites and density of synapses inntial to favourably affect this mechanism at several levels. HPA axis = hypothalamic-
M = rapid eye movement; SWS  = slow wave sleep; PLMs = periodic leg movements;
the hippocampus and prefrontal cortex (PFC) (Crochemore et al.,
2005; Tata et al., 2006) and results in abnormalities of the cau-
date, putamen and amygdala in animal models (Delgado y Palacios
et al., 2014). Chronic stress has been shown to modulate the
onset and progression of disease features in the R6/1 HD mouse
model (Mo  et al., 2014a,b). Higher glucocorticoid levels, such as
those seen in post-traumatic stress disorder (PTSD), have also been
linked to a loss of volume in the PFC and striatum and associated
impairments in cognitive function and sleep homoeostasis, which
suggests that exacerbated cortisol levels, such as those observed
in preHD, may  accelerate the onset and progression of disease fea-
tures, particularly cognitive and mood disturbances (Staufenbiel
et al., 2013; Sapolsky, 1999). Chronically elevated cortisol levels
have also been associated with reduced levels of BDNF in wild-
type and schizophrenia rodent models and in humans in other
clinical populations, including schizophrenia and major depres-
sive disorder (Issa et al., 2010; Smith et al., 1995a). This reduction
in BDNF could further exacerbate loss of volume in striatal and
extra-striatal structures and further disrupt melatonin release and
HPA-axis function. Such an association between chronic cortisol
release and reduced BDNF requires further investigation in preHD
for treatment strategies.
1.4. Effects of glucocorticoids on BDNFBDNF is essential for survival, differentiation and outgrowth of
neurons in the central and peripheral nervous systems and protects
neurons from excitotoxin-induced degeneration (Bemelmans et al.,
1999; Husson et al., 2005). BDNF is synthesised in cortical neurons
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nd delivered to the striatum via axonal transport of vesicles (Altar
t al., 1997; Goodman et al., 1996). BDNF deﬁcits have been docu-
ented in cell lines expressing mHTT and in brains of HD mouse
odels and patients at post-mortem (Ferrer et al., 2000; Gauthier
t al., 2004; Zuccato et al., 2001, 2005). Analyses of post-mortem
rain tissue of four HD subjects indicated regional BDNF deﬁcits
f between 53% and 82% in the caudate and putamen compared
o age-matched controls (Ferrer et al., 2000; Gauthier et al., 2004),
uggesting that volume loss in these regions may, at least in part,
e mediated by a lack of neurotrophic factor support.
Signiﬁcantly elevated glucocorticoids have been reported to
ecrease the expression of BDNF in animal models and other clin-
cal populations (Issa et al., 2010; Smith et al., 1995a). Chronic
tress in rodents induced by repeated restraint results in a negative
orrelation between plasma glucocorticoid levels and hippocam-
al BDNF mRNA expression (Murakami et al., 2005; Smith et al.,
995b). Furthermore, exogenous administration of glucocorticoids
s associated with a transient, dose-dependent reduction in BDNF
RNA and protein in the hippocampus of adrenalectomized (ADX)
odent models (Hansson et al., 2006; Schaaf et al., 1998). However,
ve days of oral corticosterone treatment in the R6/1 HD mouse
odel did not signiﬁcantly affect hippocampal BDNF expression,
mphasising the need to characterise the effects of chronic ele-
ated stress on BDNF levels in HD animal models and patients. It
s conceivable that elevated glucocorticoid levels, as observed in
reHD, contribute to decreased BDNF expression, thereby potenti-
ting neuronal dysfunction and cell loss in cortical and sub-cortical
rain structures.
In addition to supporting normal neuronal functioning, BDNF is
hought to be integral in the homeostatic regulation of sleep (Datta
t al., 2015). Alterations in BDNF signalling as a result of irregular
ortisol regulation may  potentiate sleep deﬁcits, which are evident
arly in HD. The interplay between glucocorticoids, neurotrophic
actor support and sleep are not well understood but are likely to be
mportant considerations in better understanding the interaction
f the HPA-axis and circadian rhythm disruption as features of HD.
.5. Pathologies of the HPA-axis and SCN in HD
mHTT causes progressive neuronal dysfunction and cell loss
n striatal and extra-striatal regions, including the hypothalamic
uclei (Tabrizi et al., 2011; Li et al., 2000). Studies in mouse mod-
ls report signiﬁcant degeneration of the hypothalamus, as well
s pituitary and adrenal pathologies (Du et al., 2012; Petersén
nd Björkqvist, 2006; Sathasivam et al., 1999; Björkqvist et al.,
006). Post-mortem and structural imaging studies in HD mutation
arriers have reported volume loss in the hypothalamus, with sig-
iﬁcant hypothalamic nuclear atrophy, neuronal loss (particularly
hat of the nucleus tuberalis lateralis (NTL) and lateral hypothala-
us  (Kremer et al., 1990, 1991)) and microglial activation (Politis
t al., 2008; Douaud et al., 2006; Gabery et al., 2010; Kassubek
t al., 2004). Post-mortem studies have also reported loss of orexin-
eleasing neurons, responsible for innervating the SCN, in the
ypothalamus in HD (Petersén et al., 2005; Aziz et al., 2008). Loss
f this neuronal population is thought to contribute to circadian
hythm disturbances, HPA-axis dysfunction and subsequent alter-
tions in cortisol release (Petersén et al., 2005). Moreover, HPA-axis
ysregulation has been proposed as a contributing factor to co-
orbid depression in neurodegenerative diseases, including HD
for a comprehensive review, see Du and Pang, (2015)).
Hypothalamic atrophy has also been reported in preHD individ-
als using voxel-based morphometry (VBM) (Soneson et al., 2010).
his may, at least in part, explain the observed alterations in cortisol
elease in preHD. A recent study, however, reported no hypothala-
ic  volume loss in preHD individuals at a 12 month follow-up scan
Gabery et al., 2015). These conﬂicting ﬁndings reinforce the needhavioral Reviews 71 (2016) 444–454
to better characterise hypothalamic and other regional volumetric
changes in preHD, and determine whether such changes mediate
or contribute to circadian rhythm disturbances and clinical features
in HD.
1.6. Circadian rhythm disruption in HD
Circadian rhythmicity is progressively disrupted in HD,
suggesting a possible bi-directional relationship with the neurode-
generative disease process (for a review see Videnovic et al. (2014)).
Support for this notion comes from transgenic animal models of
HD, such as in the R6/2, R6/1 and BACHD mice, which have shown
that circadian disruption precedes the presentation of disease fea-
tures (Morton et al., 2005; Kudo et al., 2011; Maywood et al., 2010).
Furthermore, humans with manifest HD also display circadian
rhythm abnormalities, with disturbances in rest-activity proﬁles
and abnormal day-night ratios, as well as alterations in sleep-wake
timing and melatonin and cortisol proﬁles (Morton et al., 2005;
Videnovic et al., 2014; Hurelbrink et al., 2005). The neurobiology
underlying these changes has yet to be clariﬁed.
Several studies point to alterations in the SCN as being central to
circadian disruptions in HD. For example, in the R6/2 mouse model
of HD the rhythmic transcription of core clock genes in the SCN
and other brain regions is disrupted in vivo, but then rescued when
assessed in in vitro explants, suggesting that circadian deﬁcits are
due to alterations of the intrinsic circuitry of the SCN (Morton et al.,
2005; Maywood et al., 2010). This is supported by a reduced cir-
cadian rhythm in spontaneous electrical activity in SCN neurons in
BACHD transgenic mice (Kudo et al., 2011). Histopathological stud-
ies reveal reduced protein levels of VIP and AVP within the SCN of
HD patients at post-mortem (van Wamelen et al., 2013). In trans-
genic animal models of HD, the decrease in VIP levels is associated
with circadian disruption (Fahrenkrug et al., 2007). Recent evidence
from Alzheimer’s disease (AD) patients indicates that the number
of VIP-expressing SCN neurons in the post-mortem brain correlates
with circadian rhythm amplitude of motor activity (Wang et al.,
2015).
Disruption of circadian rhythmicity has the potential to affect
a broad range of molecular, cellular and physiological processes,
most noticeably sleep (Lazar et al., 2015b; Archer et al., 2014).
Disturbances in sleep are known to have multiple negative con-
sequences on human physiology, including neuronal dysfunction
and loss of brain volume (Joo et al., 2013), metabolic distur-
bances (Schmid et al., 2015), immune dysregulation (Irwin, 2002),
impaired cardiovascular function (Zhong et al., 2005), cognitive
impairments (Lo et al., 2012) and mood disturbances (Dinges et al.,
1997). Sleep disturbance can, by itself, cause further disruption to
circadian rhythmicity (Moller-Levet et al., 2013). It is highly likely
that sleep and circadian disturbances are interrelated in HD.
1.7. Melatonin and sleep disturbance in HD
Melatonin promotes the onset of sleep by inducing the ther-
moregulatory cascade (Krauchi et al., 2000). Signiﬁcant decreases
in mean and acrophase (times of peak rhythm) melatonin levels
have been reported in manifest HD, with trends towards decreased
melatonin levels in preHD (Kalliolia et al., 2014). A temporal shift in
melatonin release has also been documented in HD mutation carri-
ers, which could explain documented sleep disturbances (Kalliolia
et al., 2014). The morning rise phase of melatonin has also been
shown to be delayed in HD individuals (Aziz et al., 2009b), which
provides a mechanism underlying the delayed sleep-wake timing
reported to occur in these patients (Aziz et al., 2010; Goodman
et al., 2010). The precise mechanism responsible for the decrease
or delayed melatonin levels observed in HD is unclear, but could
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otentially be attributed to the progressive neuronal dysfunction
n the SCN (Kalliolia et al., 2014; van Wamelen et al., 2013).
Disrupted or restricted sleep leads to increased activity of the
PA-axis (Meerlo et al., 2008). Acute sleep deprivation is associ-
ted with increased sympathetic activation, reﬂected by increases
n heart rate and blood pressure (Zhong et al., 2005) and has been
escribed as a chronic stressor that can elevate glucocorticoids and
xacerbate disease pathways, such as neuronal dysfunction and
egeneration (McEwen, 2006; Leproult et al., 1997). It is also impor-
ant to note that disturbances in sleep, particularly disruption of
low wave sleep and decreased sleep duration, result in declines in
ognitive and motor performance, as well as altered mood (Ferrie
t al., 2011; Mander et al., 2013a,b, 2015).
Studies in animal models have shown that sleep deﬁcits
an negatively affect hippocampal function, and can lead to
mpaired synaptic plasticity (long-term potentiation) and changes
n N-Methyl-d-Aspartate (NMDA) and -amino-3-hydroxy-5-
ethyl-4-isoxazolepropionic acid (AMPA) receptor signalling and
uctuations in levels of glutamate, a ligand for these receptors
Ravassard et al., 2009; Kopp et al., 2006). Sleep has been reported to
romote the formation of branch-speciﬁc dendritic spines follow-
ng motor learning in mice, with disruption of non-REM (NREM)
leep preventing the formation of branch-speciﬁc dendritic spines
Yang et al., 2014). Furthermore, sleep has been shown to drive
learance of neurotoxic waste from the central nervous system
n mice and disruption of sleep could potentially facilitate accu-
ulation of these substances (Xie et al., 2013). Sleep deﬁcits have
lso been shown to negatively affect executive functions associated
ith the PFC, such as working memory and lateral thinking, likely
ue to the differential activation of adenosine receptors and disrup-
ion of synaptic homeostasis (Lo et al., 2012; Harrison and Horne,
998; Florian et al., 2011). Loss of volume of the frontal, tempo-
al and parietal cortices are associated with sleep deﬁcits (Sexton
t al., 2014) and could also affect executive functions associated
ith these regions.
Sleep disturbances have been reported in manifest HD, with
everal studies reporting insomnia, decreased REM, slow wave
leep and sleep efﬁciency, advanced sleep phase, frequent noc-
urnal awakenings and increased periodic leg movements (PLMs)
Hansotia et al., 1985; Wiegand et al., 1991; Piano et al., 2015;
rnulf et al., 2008; Morton et al., 2005; Neutel et al., 2015). Fur-
hermore, a recent study by Lazar et al. (2015a,b) showed that
leep disruption is evident in preHD, characterised by a fragmented
leep proﬁle and a decrease in theta power during REM sleep (Lazar
t al., 2015a). These features were associated with disease burden
core. It is notable that sleep deﬁcits seem to appear at a time when
ognitive impairments also start to emerge, indicating a potential
elationship between these disease features.
Sleep deﬁcits are of particular interest in HD, as cognitive func-
ions associated with both the hippocampus and PFC are affected in
his population before disease onset (Tabrizi et al., 2011), and can
e negatively impacted by sleep disturbances, as well as increased
lucocorticoids (Blagrove et al., 1995; Oei et al., 2006; Belanoff
t al., 2001). Ultimately, alterations in circadian rhythm marked by
hanges in the molecular clock and facilitated by hypothalamic and
CN pathologies, could result in changes in melatonin release and
ncreased cortisol levels, with resultant sleep disturbances, which
re likely to potentiate neurodegeneration and associated changes
n cognitive and motor deﬁcits and mood disturbances in HD.
.8. Environmental enrichment: a comprehensive
on-pharmaceutical strategy to reduce the impact of circadian
hythm disturbances and HPA-axis dysfunction in HD
Several non-pharmaceutical strategies have been employed to
meliorate circadian and HPA-axis dysfunctions in mouse modelshavioral Reviews 71 (2016) 444–454 449
of HD, including bright light and behavioural therapy (Cuesta et al.,
2014) and environmental enrichment (EE). EE is an experimental
approach reported to change intrinsic and behavioural rest-activity
circadian rhythmicity and glucocorticoid release and has been
widely studied in transgenic and drug-induced AD, Parkinson’s dis-
ease (PD) and HD mouse models (reviewed in (Nithianantharajah
and Hannan, 2006)). EE employs exercise, cognitive and sensory
stimulation to promote neurogenesis and improve cognitive and
behavioural function, motor features and overall pathological pro-
cesses underpinning these clinical features (Nithianantharajah and
Hannan, 2006; Hannan, 2014; Lazic et al., 2006).
The ﬁrst demonstration that EE could be beneﬁcial in a genetic
animal model involved HD mice (van Dellen et al., 2000) and
demonstrated that EE could delay disease onset and progression
displayed by improved motor function and preserved peristriatal
brain structures. Ensuing investigations revealed that EE has cog-
nitive and body composition beneﬁts in R6/2 (Hockly et al., 2002)
and N171 HD mice (Schilling et al., 2004), while also ameliorat-
ing cognitive deﬁcits (Nithianantharajah et al., 2008) and affective
(depressive-like) abnormalities in R6/1 mice (Pang et al., 2009;
Renoir et al., 2013). Considering the more rapid disease progres-
sion of the R6/2 model compared to R6/1, this demonstrates that EE
is effective in both rapid and more prolonged disease progression
phenotypes.
EE has been reported to increase the length of neuronal den-
drites in the dorsomedial nucleus of the hypothalamus, which is
thought to play a role in the circadian control of sleep and wak-
ing behaviours (Chou et al., 2003), and alter stress reactivity in
outbred rats (Francis et al., 2002; Mitra and Sapolsky, 2012), and
in the female R6/1 mouse model, EE modulates HPA-axis activity
(Du et al., 2012). Furthermore, circadian rhythm disturbances have
also been ameliorated through bright light therapy and exercise
in the R6/2 mouse model (Cuesta et al., 2014). This demonstrates
that environmental interventions have the potential to modulate
functions of the HPA-axis and the SCN in mouse models of HD and
warrants further investigation into whether this can be recapitu-
lated in the human HD population.
Moreover, EE in HD mice has been shown to rescue BDNF protein
levels in the striatum and hippocampus (Spires et al., 2004), with
associated delays in disease onset, including a reduction in cogni-
tive decline (Nithianantharajah et al., 2008). These studies suggest
that modulation of HPA-axis function and circadian rhythm facil-
itated by EE may, at least in part, rescue BDNF levels, ultimately
contributing to neuroprotection and neurogenesis (Mattson, 2012).
Evidence suggests that physical activity in itself can be ben-
eﬁcial in delaying the progression of HD in mouse models. Pang
et al. (2006) demonstrated that voluntary wheel running delayed
onset of rear paw clasping, a feature of HD in mouse models, ame-
liorated cognitive deﬁcits and also normalised rearing behaviour
(Pang et al., 2006). Additionally, wheel running from a juvenile
age (4 weeks) delayed onset of rear paw clasping and of deﬁcits in
motor coordination and rescued locomotor activity and exploratory
behaviour (van Dellen et al., 2008). It has been suggested that some
of the behavioural improvements resulting from voluntary phys-
ical activity are modulated by the upregulation of monoamines,
such as serotonin, dopamine and nor-adrenaline, across several
brain regions (Renoir et al., 2011). Interestingly, wheel running is
associated with sex-dependent increases in BDNF expression, with
only female HD mice exhibiting increases in BDNF following phys-
ical activity alone and male HD mice showing increases in BDNF
only following EE (Zajac et al., 2010). This indicates that volun-
tary physical activity can up-regulate key molecules that modulate
cognitive and behavioural changes in mouse models of HD in a
sex-dependent manner.
Studies in several animal disease models have demonstrated the
importance of social interaction in mediating the beneﬁts of EE. For
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xample, co-housed AD APP/PS1 mouse models exhibit ameliora-
ion of memory deﬁcits facilitated by increased BDNF-dependent
eurogenesis in the hippocampus (Hsiao et al., 2014). Transgenic
D sheep exhibit circadian abnormalities when housed only with
ther HD ﬂock, with circadian abnormalities absent in those HD
ene positive sheep housed with wild-type sheep (Morton et al.,
014). Although physical activity and co-housing, when assessed
lone, can produce positive outcomes in mouse models of HD,
reater beneﬁcial effects are observed when used in conjunction
ith other components of EE. Such ﬁndings demonstrate that
nvironmental interventions have a positive impact on disease pro-
esses in animal models of HD and warrant further investigation
nto the translation of these programs into the human HD popula-
ion.
.9. Effects of multidisciplinary therapy on brain volume and
otential biomarkers of HD in humans
Preclinical studies show that EE has positive effects on the
athological and clinical course of HD. However translation of EE
rom the laboratory to the clinic has proven difﬁcult due to the
trict parameters of the experimental model, such as diet and
ousing conditions. Several research teams have, nevertheless,
egun to address some of these translational gaps using multidisci-
linary therapy; a complex, interdisciplinary therapeutic approach
omprising physical activity, cognitive stimulation and social inter-
ction.
Studies evaluating the utility of multidisciplinary therapy have
ocumented signiﬁcant changes in grey matter volume, as well
s improvements in memory, processing speed, balance and gait,
ood and quality of life in patients with manifest HD (Thompson
t al., 2013; Piira et al., 2013; Veenhuizen et al., 2011; Cruickshank
t al., 2015). Recent data from our research programme has shown,
n particular, that multidisciplinary therapy increases grey matter
olume in the caudate tail and dorsolateral PFC in patients with
anifest HD (Cruickshank et al., 2015). This therapy has also been
eported to improve cognitive function, quality of life and depres-
ive symptoms in patients with mild AD and cognitive impairment
ithout dementia (Santos et al., 2015) and in PD, multidisciplinary
herapy has been reported to improve motor performance, dyskine-
ias, balance and gait and slow disease progression (Frazzitta et al.,
013a, 2012, 2013b). The molecular mechanisms driving these neu-
al and clinical changes are yet to be investigated. Several lines
f evidence suggest, however, that multidisciplinary therapy may
estore normal HPA-axis function, circadian rhythmicity and basal
DNF levels, promoting neural and clinical beneﬁts in HD.
EE is capable of restoring normal HPA-axis function, circa-
ian rhythmicity and basal BDNF levels in HD mouse models (Du
t al., 2012; Cuesta et al., 2014; Zajac et al., 2010), with signiﬁcant
elays in peristriatal degeneration and cognitive and motor decline
Nithianantharajah et al., 2008; Pang et al., 2006; van Dellen et al.,
008), which could be facilitated by restoration of the HPA-axis and
ircadian rhythmicity and increases in BDNF levels. While these
ositive molecular changes are yet to be reported in patients with
D, evidence from other diseases suggests that multidisciplinary
herapy may  impact on the neuropathological and clinical course
f the disease in a similar fashion to EE. For example, in PD mul-
idisciplinary therapy has been reported to increase serum BDNF
evels and lessen clinical burden in the early stages of the disease
Frazzitta et al., 2015, 2014).
The effects of multidisciplinary therapy on HPA-axis function,
tress reactivity and circadian rhythmicity are yet to be investigated
n any disease population. Furthermore, the effects of this therapy
n BDNF in HD are also yet to be reported. However, the beneﬁts of
E on the HPA-axis, BDNF levels and circadian rhythmicity in HD
ouse models, both before disease features appear and followinghavioral Reviews 71 (2016) 444–454
onset, the increase in serum BDNF in PD patients and the increase in
brain volume in manifest HD patients following multidisciplinary
therapy, highlight the importance of assessing the effects of this
therapy on HPA-axis function, circadian rhythmicity and BDNF lev-
els in HD. It is conceivable that multidisciplinary therapy could
regulate the HPA-axis, and possibly circadian rhythm, and increase
BDNF levels, resulting in the positive brain changes observed in HD
individuals following this therapy. Rationale for this can be seen in
other populations when the effects of each of the components of
multidisciplinary therapy are evaluated individually.
Physical activity, cognitive training and social interaction have
a range of beneﬁts on striatal and extra-striatal brain structures,
HPA-axis function, circadian rhythm and BDNF levels. Higher phys-
ical activity levels are associated with increased hippocampal and
PFC volume, accompanying improvements in memory in healthy
older adults (Erickson et al., 2011; Colcombe et al., 2006) and
increased BDNF levels (de Melo Coelho et al., 2014; Pereira et al.,
2013)). The latter could be mediated by the continual induction
and eventual down-regulation of the stress response due to acute,
transient increases in cortisol following exercise (Luger et al., 1987),
leading to an adaptive stress response. The regulation of circadian
rhythmicity and melatonin levels by exercise, indicated by shifts
in onset and increases in peak melatonin release (Miyazaki et al.,
2001; Buxton et al., 2003), could also facilitate an increase in BDNF
and regulation of the HPA-axis, and lead to improvements in brain
volume and associated functions.
Cognitive training has also been documented to increase grey
matter volume in the cortex in regions involved in episodic mem-
ory in individuals with subjective memory impairment, a common
risk factor for AD (Engvig et al., 2014). Furthermore, cognitive
training has been shown to reduce stress-related symptoms and
improve sleep onset latency and efﬁciency in individuals with
stress-related exhaustion (Gavelin et al., 2015) and in older adults
with insomnia (Haimov and Shatil, 2013), respectively. The reg-
ulation of stress symptoms and improved sleep efﬁciency could
facilitate an increase in BDNF, which has been reported following
cognitive training in individuals with PD (Angelucci et al., 2015).
Lastly, social interaction has been shown to increase whole brain
volume, with associated improvements in visual attention and ver-
bal learning (Mortimer et al., 2012). Social interaction attenuates
the cortisol response to stressful stimuli, likely through coping or
resiliency mechanisms (Kirschbaum et al., 1995), which is likely
to facilitate the increase in BDNF observed in AD mouse models
following social interaction (Hsiao et al., 2014).
These ﬁndings collectively indicate that lifestyle interventions
could favourably impact on clinical and pathological aspects of
HD. Indeed, evidence from animal models and human studies
indicate that multidisciplinary therapy has signiﬁcant potential to
treat many of the clinical consequences of HPA-axis and circa-
dian rhythm disturbances in HD. Such an approach may  even have
the potential to reduce the rate and/or forestall neuropathological
changes that occur in individuals with preHD.
2. Conclusion
HD individuals exhibit a wide spectrum of clinical features
indicative of degeneration in striatal and extra-striatal structures,
including the hypothalamus. Hypothalamic pathologies are likely
to result in HPA-axis dysfunction and circadian rhythm dysregu-
lation, features which have been reported in HD mouse models
and gene-positive individuals. The consequent increase in gluco-
corticoids and dysregulation of melatonin and sleep patterns are
associated with decreased BDNF levels and have the potential to
contribute to, or even exacerbate, disease processes. Much is still
to be understood about the interaction between glucocorticoids,
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DNF and sleep. However, emerging evidence of potential strate-
ies to ameliorate negative downstream consequences of these
nteractions, suggest a positive role for multidisciplinary ther-
py. Preliminary studies using such strategies have demonstrated
avourable effects on HPA-axis and circadian rhythm disturbances
n animal models of HD, as well as other clinical populations,
owever the effects of multidisciplinary therapy on HPA-axis
ysfunction, circadian rhythmicity and BDNF levels in HD gene-
ositive individuals are yet to be investigated.
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